KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Total Debt (2019 - 2025)

Vir Biotechnology (VIR) has disclosed Total Debt for 5 consecutive years, with $17.5 million as the latest value for Q1 2025.

  • Quarterly Total Debt changed N/A to $17.5 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $17.5 million through Mar 2025, changed N/A year-over-year, with the annual reading at $16.1 million for FY2024, N/A changed from the prior year.
  • Total Debt hit $17.5 million in Q1 2025 for Vir Biotechnology, up from $16.1 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $68.5 million in Q3 2021 to a low of $16.1 million in Q4 2024.
  • Historically, Total Debt has averaged $30.5 million across 3 years, with a median of $24.4 million in 2021.
  • Biggest YoY gain for Total Debt was 457.45% in 2021; the steepest drop was 128.04% in 2021.
  • Year by year, Total Debt stood at $68.5 million in 2021, then tumbled by 76.55% to $16.1 million in 2024, then rose by 8.97% to $17.5 million in 2025.
  • Business Quant data shows Total Debt for VIR at $17.5 million in Q1 2025, $16.1 million in Q4 2024, and $68.5 million in Q3 2021.